International Agency for Research on Cancer (IARC) - Summaries & Evaluations


VOL.: 5 (1974) (p. 125)

5. Summary of Data Reported and Evaluation

5.1 Animal carcinogenicity data

Dieldrin was tested by the oral route only in mice and rats. The hepatocarcinogenicity of dieldrin in the mouse has been demonstrated and confirmed in several experiments, and some of the liver-cell tumours were found to metastasize. A dose-response effect has been demonstrated in both sexes with an increased tumour incidence in females at the lowest dose tested, 0.15 ppm in the diet (corresponding to about 0.01 mg/kg bw/day). In mice, there is no evidence of carcinogenicity in organs other than the liver.

The available data in rats have not provided evidence of carcinogenicity at levels of up to 50 ppm in the diet (corresponding to an intake of about 2.5 mg/kg bw/day).

The experiments in dogs and monkeys were too limited in duration and/or group sizes to allow any conclusions to be made.

5.2 Human carcinogenicity data

The epidemiological study carried out on occupationally exposed workers does not allow any conclusions to be made concerning the existence of an excess risk of developing cancer.

Although fat concentrations of dieldrin residues were higher in terminal cancer patients than in control patients, this finding is inconclusive as to a causal relationship.

Subsequent evaluation: Suppl. 7 (1987)

Last updated: 17 March 1998

    See Also:
       Toxicological Abbreviations
       Dieldrin (ICSC)
       Dieldrin (PIM 575)
       Dieldrin (FAO Meeting Report PL/1965/10/1)
       Dieldrin (FAO/PL:CP/15)
       Dieldrin (FAO/PL:1967/M/11/1)
       Dieldrin (FAO/PL:1968/M/9/1)
       Dieldrin (FAO/PL:1969/M/17/1)
       Dieldrin (AGP:1970/M/12/1)
       Dieldrin  (IARC Summary & Evaluation, Supplement7, 1987)